Bliss GVS Pharma Ltd

On 04-Dec, Bliss GVS Pharma Ltd witnessed a significant rise in its share price, closing at ₹169.55, up by ₹14.65 or 9.46%. This sharp increase reflects the stock’s strong outperformance relative to its sector and benchmark indices, driven by robust recent returns and favourable valuation metrics.

As of November 19, 2025, Bliss GVS Pharma is considered undervalued with a PE ratio of 15.51 and strong performance, outperforming the Sensex with a 33.10% return, while its valuation metrics are more favorable compared to peers like Sun Pharma and Divi's Lab.

As of November 18, 2025, Bliss GVS Pharma is fairly valued with a PE Ratio of 16.15 and has outperformed the Sensex with a 1-year return of 38.54%, contrasting with its peers like Sun Pharma and Cipla.

Bliss GVS Pharma's latest Q2 FY26 results show strong revenue growth of 12.27% year-on-year, but profitability is concerning due to declining margins and heavy reliance on non-operating income, indicating potential challenges ahead.

As of November 17, 2025, Bliss GVS Pharma is considered undervalued with an attractive valuation grade, featuring a PE ratio of 15.81, an EV to EBITDA of 12.78, and a PEG ratio of 0.89, significantly lower than its peers, while also outperforming the Sensex with a return of 38.96% compared to 9.50%.

Bliss GVS Pharma has experienced steady growth in net sales and profits, with net sales increasing from INR 747.45 crore in March 2022 to INR 809.73 crore in March 2025. However, rising expenditures and liabilities pose challenges despite improvements in profit before tax and consolidated net profit.

As of 13-Nov, Bliss GVS Pharma Ltd is seeing a price increase to 167.25, up 4.34%, with strong recent performance and a 42.64% return over the past year. Despite a decline in investor participation, the stock's liquidity remains adequate, indicating continued interest.

Bliss GVS Pharma has shown steady growth in net sales and profits from March 2022 to March 2025, with net sales increasing to INR 809.73 crore and profit after tax rising to INR 90.26 crore. However, total expenditure and liabilities have also increased, indicating rising costs that need monitoring.

As of 11-Nov, Bliss GVS Pharma Ltd is seeing a price increase to Rs 157.55, up 6.49%, with strong short-term performance and a total return of 22.99% over the last two days. Despite a year-to-date decline, the stock has outperformed the market over the past year, though concerns about long-term growth and reduced institutional investor participation remain.

As of November 10, 2025, the trend is mildly bullish due to daily moving averages, but caution is advised as weekly indicators show a bearish outlook, resulting in mixed signals across time frames.

As of November 10, 2025, Bliss GVS Pharma is fairly valued with a PE ratio of 14.27 and lower valuation metrics compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date underperformance of -10.14% against the Sensex, while showing strong long-term growth of 103.93% over three years.